Controlled release lipoic acid
AssigneeMedical Research Institute
InventorEdward Byrd
Life of this patent
Estimating the term…
Abstract
A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.
Claims23
-20. (canceled)
A controlled release oral dosage formulation, comprising:
- a therapeutically effective amount of an orally active antidiabetic chosen from a sulfonylurea, a biguanide and a thiazolidinedione;
- a therapeutically effective amount of lipoic acid;
- and
- an excipient material.
A method of treating a human patient, comprising:
- administering to a human patient a controlled release formulation of an orally active antidiabetic chosen from a sulfonylurea, a biguanide and a thiazolidinedione, and lipoic acid.
A method of reducing a human patient's serum glucose level, comprising:
- administering a therapeutically effective amount of an orally active antidiabetic selected from the group consisting of a sulfonylurea, a biguanide and a thiazolidinedione;
- and
- administering an oral controlled release formulation of lipoic acid.
Dependencies are inferred from the claim text.